NOVEL GENE DISCOVERED IN THE HEART
在心脏中发现的新基因
基本信息
- 批准号:6389849
- 负责人:
- 金额:$ 21.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-07-05 至 2003-07-04
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Development of the heart requires the precise spatial and temporal control of gene expression for proliferation and differentiation. During embryonic and early neonatal development, the heart grows by cell proliferation. Further growth is later established through cell enlargement, or cardiac hypertrophy. Cardiac muscle cell proliferation appears to be regulated by a separate program, distinct from the program which controls differentiation of the myocyte, unlike most other cell types. The mechanisms governing the control of cardiomyocyte proliferation are yet to be established. An understanding of these mechanisms will provide an avenue of opportunity to manipulate cellular proliferation to replace and/or repair damaged tissue sustained from cardiovascular disease. We have identified, cloned and sequenced a novel gene (TAP) in the heart which is expressed in association with myocyte proliferation. Preliminary western analysis show that the Tap protein is expressed only in the dividing cardiomyocyte and is virtually absent from the non dividing myocyte. Our hypothesis predicts that TAP is a necessary component of a signal transduction pathway required for cardiomyocyte proliferation. Our long term goal is to determine the function of Tap in the dividing myocyte. Our specific aims are to: (1) Identify cellular proteins which associated with Tap in the cardiomyocyte using the yeast two-hybrid screen and co-immunoprecipitation in order to determine how Tap may function in the cell. (2) To begin to functionally characterize Tap by over expressing and blocking its expression in cultured adult, 21-day postnatal and embryonic rat ventricular cardiomyocytes and in the HL-1 cardiac muscle cell line. Since this gene is entirely novel these studies will provide the first indication of the functional role of TAP in the myocyte, and provide a foundation for the design of rational, future in depth studies.
心脏的发育需要对增殖和分化的基因表达进行精确的空间和时间控制。 在胚胎和新生儿早期发育期间,心脏通过细胞增殖生长。 随后通过细胞增大或心脏肥大建立进一步生长。 心肌细胞增殖似乎是由一个单独的程序,不同于程序控制分化的肌细胞,不像大多数其他类型的细胞。 控制心肌细胞增殖的机制尚未建立。 对这些机制的理解将提供一个机会,操纵细胞增殖,以取代和/或修复受损组织持续心血管疾病。我们已经确定,克隆和测序一个新的基因(TAP)在心脏中表达与心肌细胞增殖。 初步的Western分析显示Tap蛋白仅在分裂的心肌细胞中表达,而在非分裂的心肌细胞中几乎不表达。 我们的假设预测,TAP是心肌细胞增殖所需的信号转导途径的必要组成部分。我们的长期目标是确定Tap在分裂的肌细胞中的功能。 我们的具体目标是:(1)利用酵母双杂交筛选和免疫共沉淀技术鉴定心肌细胞中与Tap相关的细胞蛋白,以确定Tap在细胞中的功能。 (2)开始通过在培养的成年、出生后21天和胚胎大鼠心室心肌细胞和HL-1心肌细胞系中过表达和阻断其表达来功能性地表征Tap。 由于该基因是全新的,这些研究将首次表明TAP在肌细胞中的功能作用,并为设计合理的未来深入研究提供基础。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The MRE11-NBS1-RAD50 pathway is perturbed in SV40 large T antigen-immortalized AT-1, AT-2 and HL-1 cardiomyocytes.
MRE11-NBS1-RAD50 通路在 SV40 大 T 抗原永生化 AT-1、AT-2 和 HL-1 心肌细胞中受到干扰。
- DOI:10.1093/nar/28.15.2882
- 发表时间:2000
- 期刊:
- 影响因子:14.9
- 作者:LansonJr,NA;Egeland,DB;Royals,BA;Claycomb,WC
- 通讯作者:Claycomb,WC
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM C CLAYCOMB其他文献
WILLIAM C CLAYCOMB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM C CLAYCOMB', 18)}}的其他基金
Potential Use of ES Cells for Cardiac Tissue Engineering
ES 细胞在心脏组织工程中的潜在用途
- 批准号:
7339853 - 财政年份:2007
- 资助金额:
$ 21.32万 - 项目类别:
Potential Use of ES Cells for Cardiac Tissue Engineering
ES 细胞在心脏组织工程中的潜在用途
- 批准号:
7195909 - 财政年份:2007
- 资助金额:
$ 21.32万 - 项目类别:
相似海外基金
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
- 批准号:
23K06731 - 财政年份:2023
- 资助金额:
$ 21.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
- 批准号:
23K06616 - 财政年份:2023
- 资助金额:
$ 21.32万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
- 批准号:
10597799 - 财政年份:2023
- 资助金额:
$ 21.32万 - 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
- 批准号:
EP/Y024591/1 - 财政年份:2023
- 资助金额:
$ 21.32万 - 项目类别:
Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10672364 - 财政年份:2022
- 资助金额:
$ 21.32万 - 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
- 批准号:
10385037 - 财政年份:2022
- 资助金额:
$ 21.32万 - 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
- 批准号:
10383462 - 财政年份:2022
- 资助金额:
$ 21.32万 - 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
- 批准号:
10483063 - 财政年份:2022
- 资助金额:
$ 21.32万 - 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
- 批准号:
2752732 - 财政年份:2022
- 资助金额:
$ 21.32万 - 项目类别:
Studentship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10546865 - 财政年份:2022
- 资助金额:
$ 21.32万 - 项目类别: